Bio-Path (NASDAQ:BPTH – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.02, MarketWatch Earnings reports. During the same quarter last year, the firm earned ($0.49) earnings per share.
Bio-Path Price Performance
Shares of BPTH stock opened at $0.54 on Friday. The stock’s 50 day simple moving average is $0.50 and its 200 day simple moving average is $0.95. Bio-Path has a twelve month low of $0.32 and a twelve month high of $2.35.
Institutional Trading of Bio-Path
Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Bio-Path in the first quarter valued at approximately $38,000. Renaissance Technologies LLC acquired a new stake in Bio-Path in the 2nd quarter worth $70,000. Finally, Citadel Advisors LLC bought a new position in shares of Bio-Path during the 3rd quarter worth about $35,000. Institutional investors own 5.74% of the company’s stock.
Analysts Set New Price Targets
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
- Five stocks we like better than Bio-Path
- How to Calculate Stock Profit
- Williams-Sonoma is a steal for buy-and-hold investors
- How to Use the MarketBeat Dividend Calculator
- A closer look at Warren Buffett’s latest surprise purchase
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- GE stock surges to six-year high: What’s behind the move?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.